QUILT-1.004: A Single Center, Open-label, Pharmacokinetic Study of Subcutaneous ALT-803
Latest Information Update: 08 Jun 2020
At a glance
- Drugs Nogapendekin alfa inbakicept (Primary)
- Indications Acute myeloid leukaemia; Bladder cancer; Breast cancer; Colorectal cancer; Fallopian tube cancer; Haematological malignancies; HIV infections; Liver cancer; Merkel cell carcinoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours; Squamous cell cancer
- Focus Pharmacokinetics
- Acronyms QUILT-1.004
- Sponsors Altor BioScience Corporation
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 23 Aug 2019 Status changed from active, no longer recruiting to completed.
- 08 May 2018 Planned End Date changed from 31 Mar 2018 to 31 May 2018.